Learn About Our Services

OCREVUS Access Solutions is your resource for access and reimbursement support after OCREVUS is prescribed.

Patient Navigators

Your OCREVUS Patient Navigator is your point of contact for assistance throughout your patients’ treatment, including access, reimbursement and infusion coordination support

Learn More

Reimbursement

Sample coding information and resources for denials and appeals

Learn More

Product Distribution

A list of authorized distributors and specialty pharmacies as well as information on our Spoilage Replacement Program

Learn More

Online Patient Enrollment

Submit the OCREVUS Start Form, check the status of your service requests and send messages to your OCREVUS Patient Navigator online using My Patient Solutions

Learn More

Our Commitment to Patients

Over the past 20+ years,
Genentech has helped more than

1.7 million

patients access the Genentech medicines they need.

In 2017, we helped more than

227,000

patients access the Genentech medicines they need.

Communication assistance services

OCREVUS Access Solutions employs a multilingual call center staff and offers teletypewriter (TTY) services for callers.
 

PAN=Patient Authorization and Notice of Request for Transmission of Health Information to Genentech Access Solutions and Genentech® Access to Care Foundation.

SMN=Statement of Medical Necessity.

Important Safety Information & Indication

Indications

OCREVUS is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis.

Contraindications

OCREVUS is contraindicated in patients with active hepatitis B virus infection and in patients with a history of life-threatening infusion reaction to OCREVUS.

Warnings and Precautions

Infusion Reactions:

Management recommendations for infusion reactions depend on the type and severity of the reaction. Permanently discontinue OCREVUS if a life-threatening or disabling infusion reaction occurs.

Infections:

Delay OCREVUS administration in patients with an active infection until the infection is resolved. Vaccination with live-attenuated or live vaccines is not recommended during treatment with OCREVUS and after discontinuation, until B-cell repletion.

Malignancies:

An increased risk of malignancy, including breast cancer, may exist with OCREVUS.

Most Common Adverse Reactions

RMS: The most common adverse reactions in RMS trials (incidence ≥10% and >REBIF): upper respiratory tract infections and infusion reactions.

PPMS: The most common adverse reactions (≥10% and >placebo): upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections.

For additional safety information, please see the full Prescribing Information and Medication Guide.